IPH2101

DRUG3 trials

Sponsors

Innate Pharma

Conditions

Acute Myeloid LeukemiaMultiple MyelomaSmoldering Multiple Myeloma

Phase 1

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

CompletedNCT01256073

Innate PharmaAcute Myeloid Leukemia

Start: 2007-02-28End: 2013-09-30Updated: 2014-02-28

Phase 2

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma

CompletedNCT00999830

Innate PharmaMultiple Myeloma

Start: 2009-09-30End: 2013-06-30Updated: 2016-03-24

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

CompletedNCT01222286

Innate PharmaSmoldering Multiple Myeloma

Start: 2010-09-01End: 2013-01-01Updated: 2026-05-14